Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial
BJU International · 2026-11 · 138 (5) · 831-840
DOI: 10.1111/bju.70396 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift BJU International, online erschienen am 31.07.2026. Verfasst von Lene Munk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, BCG Vaccine. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medac.
Abstract (Originalsprache)
Objectives
To evaluate the impact of personalized dwell‐time (DT) reductions on symptom prevalence and systemic toxicities in patients undergoing Bacillus Calmette–Guérin (BCG) instillation for non‐muscle invasive bladder cancer (NMIBC).
Methods
Within a multinational randomized controlled trial (North‐REG Dwell Time Study [NCT04701151]), 225 patients provided daily electronic patient‐reported outcomes data during BCG induction and maintenance cycles. Participants were randomized 1:1, stratified by clinical site, sex, and concomitant carcinoma in situ, to either a standard care arm (control) or an intervention arm. Toxicity was analysed using a ‘worst‐day’ principle to capture peak symptom burden. All patients initially received a standard 120‐min DT. In the intervention group, algorithm‐guided DT reductions (to 60 or 30 min) were triggered by real‐time symptom severity, whereas the control group maintained a 120‐min DT.
Results
At baseline, 69% vs. 71% (control vs. intervention) of participants reported pre‐existing symptoms, primarily lower urinary tract symptoms such as pollakiuria and urgency. During induction, the intervention group experienced significantly lower rates of urgency at week 3 (34% vs. 47%, P = 0.04) and week 6 (32% vs. 49%, P = 0.01). Significant reductions were also observed during maintenance at week 9 for systemic symptoms (30% vs. 61%, P < 0.001) and fatigue (22% vs. 47%, P = 0.001). Total adherence to the 15‐instillation protocol was 38% in the intervention group and 40% in the control group.
Conclusion
Daily electronic patient‐reported outcomes monitoring revealed that patients with NMIBC have a high baseline symptom burden prior to BCG therapy. Symptom‐guided DT reductions may reduce local urgency and systemic toxicity and improve treatment tolerability. However, treatment completion does not seem to be affected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.
- Department of Urology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Urology, Aalborg University Hospital, Aalborg, Denmark.
ORCID-Profile: Lene Munk, Juan Luis Vásquez, Viveka Ströck, Tomas Jerlsström, Maria Skydt Lindgren, Jørgen Bjerggaard Jensen, Charlotte Graugaard-Jensen
Förderung
- Medac
Zitieren
APA
Munk, L., Hyldgaard, J. M., Kumasegaram, V., Milling, R. V., Brandt, S. B., Vásquez, J. L., Fabrin, K., Lam, G. W., Bro, L., Gudjonsson, S., Ströck, V., Jerlsström, T., Thiel, T., Lindgren, M. S., Jensen, J. B., & Graugaard-Jensen, C. (2026). Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial. BJU International, 138(5), 831-840. https://doi.org/10.1111/bju.70396
Vancouver
Munk L, Hyldgaard JM, Kumasegaram V, Milling RV, Brandt SB, Vásquez JL, et al. Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial. BJU International. 2026;138(5):831-840. doi:10.1111/bju.70396
BibTeX
@article{Munk2026,
author = {Munk, Lene and Hyldgaard, Josephine Maria and Kumasegaram, Vanaja and Milling, Rikke Vilsbøl and Brandt, Simone Buchardt and Vásquez, Juan Luis and Fabrin, Knud and Lam, Gitte Wrist and Bro, Lasse and Gudjonsson, Sigurður and Ströck, Viveka and Jerlsström, Tomas and Thiel, Tomas and Lindgren, Maria Skydt and Jensen, Jørgen Bjerggaard and Graugaard-Jensen, Charlotte},
title = {Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial},
journal = {BJU International},
year = {2026},
volume = {138},
number = {5},
pages = {831--840},
doi = {10.1111/bju.70396}
}
EUVIMED